Influence of exercise intensity in older persons with unchanged habitual nutritional intake: skeletal muscle and endocrine adaptations.
Long-term adherence to training programmes is difficult to attain. Yet, the benefits of exercise to general health and well-being are undeniable. Any measure to demonstrate the minimum required exercise for maximal benefit to a person is a promising avenue towards increasing the uptake and adherence to physical activity for the general public. The purpose of this study was to compare the effects of two different intensities of resistance training in healthy older adults. We hypothesised that compared to high-intensity resistance exercise, relatively low training intensity could also improve in vivo markers of healthy physiologic and endocrine functions in previously sedentary older individuals. Thirty (out of a possible 34 recruited) older adults were randomly assigned to low (LowR, i.e. approximately 40% one repetition maximum (1RM)) versus high-resistance training (HighR, i.e. approximately 80% 1RM) for 12 weeks. Neither intervention significantly impacted upon body composition markers including: body mass index (BMI), waist/hip ratio and bioelectric impedance. Muscle strength data showed an advantage for the HighR protocol with 51 +/- 4% and 22.4 +/- 10.2% (P < 0.05) improvements in 1RM strength and bilateral knee extension torque, respectively, compared with 17 +/- 1% and 10.3 +/- 4.7% (P < 0.05) increments in 1RM strength and bilateral torque in the LowR group. Unilateral torque did not change significantly in either group. Quadriceps muscle thickness data also showed a significantly greater benefit of the HighR protocol (5.8 +/- 2.6% increase) compared with the LowR protocol (no change). Functional ability tests, including Get-up-and-go (GUG), Standing from lying and the 6-min walk, showed changes of -11.6 +/- 4.8%, -15.6% and 8.5 +/- 1.7% (P < 0.05), respectively, in HighR compared with only one significant improvement in the LowR, namely a -10.8 +/- 3% (P < 0.05) improvement in the GUG test. Overnight fasting serum levels of IGFBP-3 increased, NPY decreased and TNF-alpha decreased significantly in the LowR group. Serum levels of glucose increased and NPY decreased significantly in HighR. Circulating levels of I, IL-6 and IGF-1 did not change with either intervention. In vivo physiologic changes show functional advantages for older persons carrying out high-resistance training. At the endocrine level, such an advantage is not clear. In fact, in terms of changes in sera levels of fasting glucose, IGFBP-3 and TNF-alpha, there appears to be an advantage to carrying out the lower intensity exercises for the aged populations where endocrine adaptations are key.
Onambélé-Pearson
Gladys Leopoldine
GL
Department of Exercise and Sport Science, Manchester Metropolitan University, Hassall Road, Alsager ST7 2HL, UK. g.pearson@mmu.ac.uk
Breen
Leigh
L
Stewart
Claire E
CE
D000222:Adaptation, Physiological; D000368:Aged; D001786:Blood Glucose / Q000378:metabolism*; D002149:Energy Intake; D015444:Exercise; D005247:Feeding Behavior; D005260:Female; D006801:Humans; D018972:Insulin-Like Growth Factor Binding Protein 3 / Q000378:metabolism*; D007334:Insulin-Like Growth Factor I / Q000378:metabolism*; D015850:Interleukin-6 / Q000378:metabolism*; D007717:Knee / Q000502:physiology; D008297:Male; D018482:Muscle, Skeletal / Q000378:metabolism*; D012399:Rotation; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism*
D001786:Blood Glucose; D018972:Insulin-Like Growth Factor Binding Protein 3; D015850:Interleukin-6; D014409:Tumor Necrosis Factor-alpha; D007334:Insulin-Like Growth Factor I
Gerontology. 2000 Sep-Oct;46(5):249-57
10965180
Z Gerontol Geriatr. 1999 Dec;32(6):425-32
10654381
Am J Clin Nutr. 1991 Apr;53(4):821-5
2008859
J Appl Physiol (1985). 2006 Aug;101(2):531-44
16614355
Endocrine. 1997 Aug;7(1):57-60
9449033
Sports Med. 2008;38(9):781-93
18712944
J Appl Physiol (1985). 1991 May;70(5):1912-6
1864770
Sports Med. 2008;38(7):579-606
18557660
J Appl Physiol (1985). 1992 May;72(5):1780-6
1601786
Clin Endocrinol (Oxf). 1996 Dec;45(6):681-8
9039333
J Biomech. 2008 Nov 14;41(15):3133-8
18976996
J Neurol Sci. 1988 Apr;84(2-3):275-94
3379447
Neuropeptides. 1996 Apr;30(2):159-65
8771558
Am J Physiol. 1997 Oct;273(4):R1557-61
9362324
J Appl Physiol (1985). 1999 Sep;87(3):982-92
10484567
Annu Rev Nutr. 2002;22:309-23
12055348
J Clin Endocrinol Metab. 2004 Apr;89(4):1844-8
15070954
J Appl Physiol (1985). 2005 Jul;99(1):95-102
15746299
Mech Ageing Dev. 2003 Mar;124(3):287-99
12663126
J Gerontol A Biol Sci Med Sci. 1996 Nov;51(6):M270-5
8914498
Am J Physiol. 1989 Mar;256(3 Pt 1):E352-6
2646944
Aging (Milano). 1997 Feb-Apr;9(1-2):106-11
9177593
J Physiol. 2004 Feb 1;554(Pt 3):803-13
14608013
J Appl Physiol (1985). 1988 Mar;64(3):1038-44
3366726
Scand J Med Sci Sports. 2010 Feb;20(1):5-9
19558380
Sports Med. 2000 Nov;30(5):327-46
11103847
Growth Horm IGF Res. 2009 Apr;19(2):146-55
18812263
Appl Physiol Nutr Metab. 2006 Oct;31(5):557-64
17111010
Acta Physiol Scand. 1990 Sep;140(1):41-54
2275404
Regul Pept. 2007 Mar 1;139(1-3):65-71
17113660
Am J Physiol. 1990 Jun;258(6 Pt 1):E990-8
2360629
Arch Phys Med Rehabil. 1998 Jan;79(1):24-30
9440412
Med Sci Sports Exerc. 2002 Jul;34(7):1199-206
12131263
J Physiol Pharmacol. 2006 Nov;57 Suppl 6:55-61
17228087
J Appl Physiol (1985). 2003 Oct;95(4):1717-27
12970377
J Gerontol A Biol Sci Med Sci. 2001 May;56(5):M281-6
11320107
J Appl Physiol (1985). 1997 Aug;83(2):623-30
9262461
Clin Physiol. 1997 Sep;17(5):459-74
9347195
J Appl Physiol (1985). 1999 Jan;86(1):195-201
9887131
Muscle Nerve. 2003 Nov;28(5):601-8
14571463
Biochem Biophys Res Commun. 2004 May 14;317(4):1045-51
15094374
J Gerontol. 1990 Jul;45(4):B125-8
2365961
J Am Coll Nutr. 1995 Dec;14(6):587-94
8598419
J Gerontol A Biol Sci Med Sci. 2000 Dec;55(12):M757-60
11129399
J Gerontol A Biol Sci Med Sci. 2003 Oct;58(10):M918-22
14570859
Sports Med. 2005;35(4):339-61
15831061
Am J Physiol. 1996 May;270(5 Pt 1):E864-72
8967476
Exp Gerontol. 2007 Aug;42(8):733-44
17624709
Chronobiol Int. 2005;22(6):1013-27
16393705
Clin Physiol Funct Imaging. 2004 Mar;24(2):85-90
15056180
FASEB J. 2001 Feb;15(2):475-82
11156963
J Am Geriatr Soc. 1999 Oct;47(10):1208-14
10522954
Clin Endocrinol (Oxf). 2005 Jan;62(1):114-8
15638879
Can J Sport Sci. 1992 Mar;17(1):3-7
1322766
Acta Physiol Scand. 2003 Jan;177(1):69-78
12492780
J Gerontol A Biol Sci Med Sci. 1995 Nov;50 Spec No:11-6
7493202
JAMA. 1990 Jun 13;263(22):3029-34
2342214
Arch Phys Med Rehabil. 2001 Jul;82(7):872-8
11441371
Sports Med. 2006;36(3):215-38
16526834
Acta Physiol Scand. 2001 Jan;171(1):51-62
11350263
Aging Cell. 2004 Aug;3(4):151-60
15268748
Endocr Rev. 1995 Feb;16(1):3-34
7758431
J Am Geriatr Soc. 1995 Oct;43(10):1081-7
7560695
Pituitary. 2007;10(2):129-33
17487588
Muscle Nerve. 2006 Jun;33(6):792-800
16523507
Acta Physiol Scand. 1999 Jan;165(1):51-6
10072097
Clin Physiol. 1985 Apr;5(2):145-54
3888498
Diabetologia. 1985 Jul;28(7):412-9
3899825
Br J Pharmacol. 2008 Jun;154(3):557-68
18500379
J Appl Physiol (1985). 2003 Dec;95(6):2229-34
12844499
J Cardiopulm Rehabil Prev. 2007 Sep-Oct;27(5):298-302
17885508
J Appl Physiol (1985). 2000 Apr;88(4):1321-6
10749826